EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

COVID ‐19 vaccination around the time of conception and risk of placenta‐mediated adverse pregnancy outcomes

Annette K Regan iD, Liam Bruce, Carolina Lavin Venegas, Eszter Török, Robert W Platt iD, Christopher A Gravel, Gillian D Alton, Sheryll Dimanlig-Cruz, Prakesh S Shah iD, Jon Barrett, Mark C Walker, Darine El-Chaâr iD und 10 weitere

Acta Obstetricia et Gynecologica Scandinavica · 2025

DOI: 10.1111/aogs.70025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Obstetricia et Gynecologica Scandinavica, 2025. Verfasst von Annette K Regan und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA. Hauptthemen laut MEDLINE: COVID-19 Vaccines, Pregnancy Outcome, COVID-19, Vaccination. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Public Health Agency of Canada, Norges Forskningsråd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Although numerous studies have documented no association between COVID‐19 vaccination during pregnancy and maternal and fetal health outcomes, fewer studies have evaluated fetal health effects after COVID‐19 vaccination around the time of conception and early pregnancy, a time when maternal exposures may affect early placentation and the subsequent risk of placenta‐mediated adverse pregnancy outcomes. Material and Methods We used province‐wide databases in Ontario to conduct a population‐based cohort study including all live and stillbirths ≥20 weeks' gestation with a last menstrual period (LMP) between April 1 and December 31, 2021. We deterministically linked birth registry data to the vaccine registry for all 80 253 eligible pregnancies; 31 209 (38.9%) received ≥1 dose of the COVID‐19 vaccine around the time of conception or first trimester. Using Cox regression, we estimated propensity score weighted hazard ratios (aHR) and 95% confidence intervals (CI) for associations between ≥1 dose of mRNA COVID‐19 vaccine during the periconceptional/first trimester exposure window (28 days before the LMP to the end of first trimester) and study outcomes: hypertensive disorders (gestational hypertension, preeclampsia, eclampsia), placental abruption, preterm birth (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesPregnancy OutcomeCOVID-19VaccinationHumansFemalePregnancyAdultOntarioPremature BirthStillbirthFertilizationSARS-CoV-2Cohort StudiesInfant, Newborn

Stichwörter der Autor:innen

COVID‐19 vaccinesfirstplacentapregnancypregnancy trimester

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, USA.
  • Better Outcomes Registry & Network (BORN) Ontario, Ottawa, Ontario, Canada.
  • Children's Hospital of Eastern Ontario (CHEO) Research Institute, Ottawa, Ontario, Canada.
  • Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
  • School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.

ORCID-Profile: Annette K Regan, Robert W Platt, Prakesh S Shah, Darine El-Chaâr, Nannette Okun

Förderung

  • NIAID NIH HHS
  • Public Health Agency of Canada
  • Norges Forskningsråd
  • National Institute of Allergy and Infectious Diseases
  • NordForsk

Zitieren

APA

Regan, A. K., Bruce, L., Lavin Venegas, C., Török, E., Platt, R. W., Gravel, C. A., Alton, G. D., Dimanlig-Cruz, S., Shah, P. S., Barrett, J., Walker, M. C., El-Chaâr, D., Wilson, K., Sprague, A. E., Buchan, S. A., Kwong, J. C., Wilson, S. E., Håberg, S. E., Okun, N., …, & Fell, D. B. (2025). COVID ‐19 vaccination around the time of conception and risk of placenta‐mediated adverse pregnancy outcomes. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.70025

Vancouver

Regan AK, Bruce L, Lavin Venegas C, Török E, Platt RW, Gravel CA, et al. COVID ‐19 vaccination around the time of conception and risk of placenta‐mediated adverse pregnancy outcomes. Acta Obstetricia et Gynecologica Scandinavica. 2025. doi:10.1111/aogs.70025

BibTeX
@article{Regan2025,
  author = {Regan, Annette K and Bruce, Liam and Lavin Venegas, Carolina and Török, Eszter and Platt, Robert W and Gravel, Christopher A and Alton, Gillian D and Dimanlig-Cruz, Sheryll and Shah, Prakesh S and Barrett, Jon and Walker, Mark C and El-Chaâr, Darine and Wilson, Kumanan and Sprague, Ann E and Buchan, Sarah A and Kwong, Jeffrey C and Wilson, Sarah E and Håberg, Siri E and Okun, Nannette and Dhinsa, Tavleen and Dunn, Sandra and Fell, Deshayne B},
  title = {COVID ‐19 vaccination around the time of conception and risk of placenta‐mediated adverse pregnancy outcomes},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2025},
  doi = {10.1111/aogs.70025}
}
Kostenlos starten →